Search Results - "de Bever, Laureen"

Enzymatic glycan remodeling-metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering by Wijdeven, Marloes A., van Geel, Remon, Hoogenboom, Jorin H., Verkade, Jorge M. M., Janssen, Brian M. G., Hurkmans, Inge, de Bever, Laureen, van Berkel, Sander S., van Delft, Floris L.

“…Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic…”
Get full text

Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates by Khera, Eshita, Dong, Shujun, Huang, Haolong, de Bever, Laureen, van Delft, Floris L, Thurber, Greg M

“…After several notable clinical failures in early generations, antibody-drug conjugates (ADC) have made significant gains with seven new FDA approvals within…”
Get full text

Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology by de Bever, Laureen, Popal, Sorraya, van Schaik, Jord, Rubahamya, Baron, van Delft, Floris L., Thurber, Greg M., van Berkel, Sander S.

“…GlycoConnect technology can be readily adapted to provide different drug-to-antibody ratios (DARs) and is currently also evaluated in various clinical…”
Get full text